TB-500 Dosage Protocol: What the Research Actually Supports

Search “TB-500 dosage protocol” and you will find a hundred confident charts telling you to load 5 mg a week, then taper to 2 mg. What almost none of them tell you is where those numbers come from. The honest answer is uncomfortable: there is no dosing label, no approved protocol, and no completed human trial of injectable TB-500. The figures you see are extrapolated from rat studies and gym-floor anecdote, dressed up to look clinical.

If you are going to read about this peptide, read about it with your eyes open. Here is what the actual science and the regulators say, separated cleanly from what the supplement internet wants you to believe.

What is the standard TB-500 dosage protocol?

There is no FDA-approved TB-500 dosage. The protocols circulating online typically describe a loading phase of roughly 2 to 5 mg injected subcutaneously twice weekly for 4 to 6 weeks, followed by a maintenance dose of about 2 mg once weekly. These figures come from animal research and practitioner observation, not from controlled human trials, and TB-500 remains a research compound not approved for human use.

That answer is the whole story in miniature. The commonly repeated “loading then maintenance” structure is real in the sense that it is what people circulate, but it rests on no human pharmacokinetic data. When dosing guides quote a loading phase of 2 to 5 mg twice per week and a maintenance dose near 2 mg weekly (Peptide Dosing Protocols, 2026), they are honest enough, in the fine print, to call these “research-context” plans extrapolated from animal data.

What exactly is TB-500 and how does it relate to thymosin beta-4?

TB-500 is a synthetic fragment marketed as a stand-in for thymosin beta-4 (Tβ4), a naturally occurring protein involved in cell migration, actin binding, and tissue repair. The marketing leans hard on the legitimate Tβ4 research, and that is where the confusion starts.

Here is the distinction that matters. Real human clinical work exists for the full-length thymosin beta-4 protein, not for the injected TB-500 fragment that buyers actually use. The biotech RegeneRx has run thymosin beta-4 candidates through clinical development for ophthalmic, cardiac, and dermal indications (RegeneRx, 2015). Their lead eye-drop candidate, RGN-259, reached a Phase III trial in neurotrophic keratopathy where 6 of 10 treated patients achieved complete corneal healing after four weeks versus 1 of 8 on placebo, with disease-stage improvement reaching statistical significance by day 43 (Sosne et al., 2022, PMC9820614).

That is genuine, peer-reviewed evidence. But notice what it is: a topical eye drop of the full protein for a corneal disease. It is not an injection of a fragment for a torn hamstring. You cannot borrow the credibility of an eye-drop trial to validate a subcutaneous recovery protocol. The two share a molecule family and almost nothing else.

Is there any human trial that supports the injection dosing people use?

No. This is the part the dosage charts quietly skip. There are no controlled human clinical trials of injectable TB-500, and no completed Phase 2 or Phase 3 trials of systemic injectable TB-500 for muscle, tendon, or joint indications have been published (TrimRx evidence review, 2026). Early human research on thymosin beta-4 has focused on ophthalmic and cardiac settings, and those results cannot be generalized to a recovery or injury-prevention claim.

So when a protocol tells you to inject 2.5 mg twice a week “for tendon healing,” understand the logic chain: a number derived from rodent models, applied to a use case that has never been tested in a human trial, sold with the implied authority of unrelated eye and heart studies. That is not a dosing protocol in any clinical sense. It is a convention.

What dosing structure do the online protocols actually describe?

For completeness, and without endorsement, here is the structure most commonly circulated so you can recognize it for what it is:

• Loading phase: approximately 2 to 5 mg per week, usually split into two subcutaneous injections, run for 4 to 6 weeks (Peptide Nerds dosage guide).
• Maintenance phase: approximately 2 mg once weekly for ongoing cycles.
• Route: subcutaneous injection in most circulating human protocols, while many of the underlying animal studies used intramuscular or intraperitoneal routes instead.

The route mismatch alone should give you pause. When the human convention does not even match the administration route of the animal data it is supposedly based on, you are looking at folklore, not pharmacology. No reliable human half-life or clearance data exists to anchor these intervals, which is why the same guides cannot tell you why it is twice a week rather than three times.

Is TB-500 legal, and is it banned in sport?

TB-500 is not FDA-approved for human use and is sold only as a research compound. The regulatory picture is also shifting. The FDA placed TB-500 in 503A Category 2 in 2023, flagging significant safety concerns for compounding, and in 2026 scheduled it for review by the Pharmacy Compounding Advisory Committee on July 23, 2026 to decide possible inclusion on the 503A Bulks List (RealPeptides regulatory summary, 2026). “Under committee review” is not the same as “approved.”

For anyone who competes, the answer is simpler and harder. The World Anti-Doping Agency has prohibited thymosin beta-4 and its derivatives, explicitly naming TB-500, under Section S2 of the Prohibited List, banned at all times in and out of competition (BSCG, 2026). The ban has stood since 2012. A positive test can cost an athlete a multi-year suspension. If you are tested under WADA rules, this is a non-starter, full stop.

What does the safety evidence actually show?

Honest version: published thymosin beta-4 research has reported relatively few adverse events, but the data is thin and indication-specific. In the RGN-259 eye-drop Phase III trial, only one treatment-related adverse event occurred and no patients withdrew for safety reasons (Sosne et al., 2022). That is reassuring for a topical eye drop and tells you very little about repeated subcutaneous self-injection of a fragment from an unregulated vial.

The real-world risks with grey-market peptides are rarely about the molecule in isolation. They are about purity, sterility, dosing accuracy, and contamination in products that no agency inspects. When there is no human trial defining a safe dose, “few reported side effects” is a statement about the absence of data, not the presence of safety.

If you want the broader context on how peptides are studied and regulated, see our overview on peptides explained.

Frequently asked questions

Is there an official TB-500 dosage chart?

No. No regulatory body has published a dosing label for TB-500 because it is not approved for human use. Every chart you find online is built from animal studies and user reports, not from human clinical trials.

How is TB-500 different from BPC-157?

Both are research peptides marketed for recovery, and both lack completed human efficacy trials for that use. TB-500 is a thymosin beta-4 fragment, while BPC-157 is a separate gastric-derived peptide. Neither is FDA-approved, and stacking them does not add clinical evidence.

Will TB-500 cause a failed drug test?

Yes, for athletes under WADA jurisdiction. Thymosin beta-4 and its derivatives, including TB-500, are banned at all times under Section S2 of the WADA Prohibited List, with sanctions that can reach multiple years.

Does the eye-drop trial prove TB-500 injections work?

No. The Phase III evidence is for a topical eye-drop formulation of the full thymosin beta-4 protein in a corneal disease. It does not validate injected TB-500 fragment for muscle, tendon, or joint recovery, which has never been tested in a controlled human trial.

This article is for informational purposes only and is not medical advice. TB-500 is not approved for human use; do not start, stop, or change any treatment without consulting a qualified clinician.